Journal
LANCET ONCOLOGY
Volume 13, Issue 9, Pages E392-E402Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(12)70235-8
Keywords
-
Categories
Funding
- Royal College of Surgeons of Edinburgh
- Royal College of Surgeons of Ireland
- Royal College of Surgeons of England
- British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS, Paton-Massor Memorial Fund)
- Mason Medical Research Foundation
Ask authors/readers for more resources
Surgery is the most effective curative treatment for various tumour types. Despite a current preference for conservative surgery, radical excision retains a clearly defined role in modern management of locoregional disease. Extirpative defects are reconstructed routinely using free-tissue transfer from a distant donor site. Although these free flaps currently provide no direct therapeutic benefit, advances in gene-delivery techniques off er the possibility to genetically modify flaps to produce potent targeted treatments with greater anatomical control. Several promising therapeutic strategies, including virus-directed enzyme prodrug therapy, genetic radionuclide therapy, and free-flap radioprotection, have the potential to extend the role of the free flap beyond its immediate goal of restoring form and function to patients, but challenges exist. Work to translate therapeutic free-tissue transfer from preclinical study to clinical use is in progress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available